CY1114171T1 - Συζευγματα αλλεργιογονων γατας και χρησεις τους - Google Patents

Συζευγματα αλλεργιογονων γατας και χρησεις τους

Info

Publication number
CY1114171T1
CY1114171T1 CY20131100638T CY131100638T CY1114171T1 CY 1114171 T1 CY1114171 T1 CY 1114171T1 CY 20131100638 T CY20131100638 T CY 20131100638T CY 131100638 T CY131100638 T CY 131100638T CY 1114171 T1 CY1114171 T1 CY 1114171T1
Authority
CY
Cyprus
Prior art keywords
cat
antigen
compositions
vlp
conjunctions
Prior art date
Application number
CY20131100638T
Other languages
English (en)
Inventor
Martin Bachmann
Monika Bauer
Klaus Dietmeier
Nicole Schmitz
Stephan Utzinger
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of CY1114171T1 publication Critical patent/CY1114171T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η παρούσα εφεύρεση είναι στο πεδίο της ιατρικής, της δημόσιας υγείας, της ανοσολογίας, της μοριακής βιολογίας και της ιολογίας. Η εφεύρεση παρέχει συνθέσεις οι οποίες περιλαμβάνουν ένα ιόμορφο σωματίδιο (VLΡ) ή ένα σωμάτιο ιού και τουλάχιστον ένα αντιγόνο, ειδικότερα τουλάχιστον ένα αντιγόνο γάτας, και πιο συγκεκριμένα τουλάχιστον ένα αντιγόνο γάτας το οποίο είναι ένα ανθρώπινο αλλεργιογόνο. Σε ορισμένες υλοποιήσεις, το αντιγόνο είναι ένα Fel d1 αντιγόνο ή ένα θραύσμα αυτού, ομοιοπολικά συνδεδεμένο με το VLP. Η εφεύρεση επίσης παρέχει μεθόδους για παρασκευή των συνθέσεων. Οι συνθέσεις της εφεύρεσης επάγουν αποτελεσματικές άνοσες αποκρίσεις, ειδικότερα αποκρίσεις αντισωμάτων, σε θηλαστικά, ειδικότερα ανθρώπους. Οι συνθέσεις και μέθοδοι της εφεύρεσης είναι χρήσιμες στην παραγωγή εμβολίων, ειδικότερα για την αντιμετώπιση και/ή πρόληψη αλλεργιών σε πιτυρίδα γάτας και άλλα αντιγόνα και αλλεργιογόνα γάτας.
CY20131100638T 2005-03-18 2013-07-26 Συζευγματα αλλεργιογονων γατας και χρησεις τους CY1114171T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66291805P 2005-03-18 2005-03-18
EP06725140.5A EP1868642B1 (en) 2005-03-18 2006-03-17 Cat allergen fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
CY1114171T1 true CY1114171T1 (el) 2016-08-31

Family

ID=36843236

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100638T CY1114171T1 (el) 2005-03-18 2013-07-26 Συζευγματα αλλεργιογονων γατας και χρησεις τους

Country Status (19)

Country Link
US (3) US7767212B2 (el)
EP (1) EP1868642B1 (el)
JP (2) JP5302671B2 (el)
KR (1) KR20070112225A (el)
CN (2) CN103203016A (el)
AU (1) AU2006224529B2 (el)
BR (1) BRPI0608455A2 (el)
CA (1) CA2599218C (el)
CY (1) CY1114171T1 (el)
DK (1) DK1868642T3 (el)
ES (1) ES2424229T3 (el)
IL (1) IL185103A0 (el)
MX (1) MX2007011160A (el)
NZ (1) NZ561040A (el)
PL (1) PL1868642T3 (el)
PT (1) PT1868642E (el)
RU (1) RU2414239C2 (el)
WO (1) WO2006097530A2 (el)
ZA (1) ZA200707413B (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
EP1532167B1 (en) * 2002-07-17 2012-01-25 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
RU2450827C2 (ru) * 2002-07-19 2012-05-20 Цитос Биотехнологи Аг Композиции вакцин, содержащие наборы антигенов в виде амилоида бета 1-6
US7767212B2 (en) * 2005-03-18 2010-08-03 Cytos Biotechnology Ag CAT allergen conjugates and uses thereof
EP1973608A1 (en) * 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2007113633A2 (en) * 2006-04-03 2007-10-11 Pfizer Products Inc. Immunogenic compositions comprising cat allergen fel dl
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
WO2007144150A1 (en) 2006-06-12 2007-12-21 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
CA2664157C (en) 2006-09-29 2015-12-01 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
US9388236B2 (en) 2007-07-09 2016-07-12 Nestec Sa Methods for reducing allergies caused by environmental allergens
EP2705846B1 (en) * 2007-07-09 2017-06-21 Nestec S.A. Methods for reducing allergies caused by environmental allergens
CA2698397C (en) 2007-09-18 2018-03-27 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
EP2042193A1 (en) * 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
CA2733589C (en) 2008-08-08 2021-07-13 Ligocyte Pharmaceuticals, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
DE112010006063B4 (de) * 2009-11-05 2018-12-27 Novici Biotech Llc Erzeugung von Antigenen, virusartigen Partikeln über Protein-Protein-Bindungen
US8321012B2 (en) 2009-12-22 2012-11-27 The Invention Science Fund I, Llc Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject
CN105031637A (zh) 2011-07-11 2015-11-11 武田疫苗股份有限公司 胃肠外诺如病毒疫苗配制剂
JP2015503907A (ja) 2011-12-22 2015-02-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 真核細胞のための全長抗体提示システムおよびその使用
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
EP3587455A1 (en) * 2012-10-23 2020-01-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
CA2922113C (en) 2013-08-23 2023-05-23 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
JP2017512213A (ja) 2013-12-19 2017-05-18 ネステク ソシエテ アノニム 環境中のネコアレルゲンを減少するための組成物及び方法
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
EP3244915A1 (en) 2015-01-15 2017-11-22 University of Copenhagen Virus-like particle with efficient epitope display
WO2016192788A1 (en) * 2015-06-03 2016-12-08 Universität Zürich Prorektorat Mnw Methods and compositions for preventing and treating cat or dog dander allergy
EP3347046B1 (en) * 2015-09-08 2022-10-19 Universität Zürich Compositions against cat allergy
US11129882B2 (en) 2015-10-30 2021-09-28 University Of Copenhagen Virus like particle with efficient epitope display
CN105219742A (zh) * 2015-11-10 2016-01-06 海南大学 一种展示重组猫致敏原rFel d 1蛋白的免疫增强型病毒样颗粒、其表达载体及其制备与应用
WO2017179025A1 (en) 2016-04-15 2017-10-19 Alk-Abelló A/S Epitope polypeptides of ragweed pollen allergens
FR3054547B1 (fr) * 2016-07-29 2020-06-05 Angany Inc. Particules pseudo-virales et leurs utilisations
US11352417B2 (en) 2016-12-22 2022-06-07 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
AU2019406749A1 (en) 2018-12-20 2021-05-27 Saiba AG Virus-like particles of CMV modified by fusion
CN118871591A (zh) * 2022-03-18 2024-10-29 电化株式会社 包含通过接头连接的衣壳蛋白的病毒样颗粒
CN114933639B (zh) * 2022-05-05 2023-12-29 中国农业科学院兰州兽医研究所 非洲猪瘟病毒p72N抗原表位蛋白及其制备方法和用途
CN117004650B (zh) * 2023-06-25 2024-05-14 山东立菲生物产业有限公司 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163778A (en) * 1978-05-04 1979-08-07 The Foundation for the Study of Asthma and Related Diseases Asthma immunotherapy
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
JPH03504975A (ja) * 1988-06-14 1991-10-31 セル―エスシーアイ　コーポレイション 異種官能性細胞免疫剤、それを含有するワクチン及びその使用方法
US6120769A (en) * 1989-11-03 2000-09-19 Immulogic Pharmaceutical Corporation Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
WO1992011291A1 (en) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
GB9114003D0 (en) * 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
GB9213601D0 (en) * 1992-06-26 1992-08-12 Mastico Robert A Protein based delivery system
JPH10505356A (ja) 1994-09-02 1998-05-26 イミユロジク・フアーマシユーチカル・コーポレーシヨン ヒトへの投与のための組成物および方法、抗原特異的免疫応答のダウンレギュレーションを行うことが可能なペプチド
US6759234B1 (en) * 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
WO1996030523A2 (en) 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
CA2315537A1 (en) * 1997-12-16 1999-06-24 Regents Of The University Of Minnesota Methods to treat undesirable immune responses
AR020102A1 (es) 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
WO2000020032A1 (en) 1998-10-06 2000-04-13 Trustees Of Dartmouth College RECOMBINANT CAT ALLERGEN, Fel dI, EXPRESSED IN BACULOVIRUS FOR DIAGNOSIS AND TREATMENT OF CAT ALLERGY
CA2347411C (en) * 1998-10-21 2012-04-03 The Government Of The United States Of America Virus-like particles for the induction of autoantibodies
EP1135162B1 (en) * 1998-11-30 2008-10-29 Cytos Biotechnology AG Ordered molecular presentation of allergens, method of preparation and use
UA77152C2 (en) 1999-09-25 2006-11-15 Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
CA2407897A1 (en) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
CZ20031653A3 (en) 2000-11-16 2004-03-17 Alk-Abelló A/S Mutant allergens
EP1221317A1 (en) * 2000-12-28 2002-07-10 SHAN-Beteiligungsgesellschaft m.b.H. Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins
DE60032250T2 (de) 2000-12-28 2007-03-15 Biomay Produktions- Und Handels-Aktiengesellschaft Behandlung von Allergien
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
DK1499349T3 (da) 2001-03-02 2010-04-06 Univ Rockefeller Rekombinante hybrid-allergenkonstrukter med reduceret allergenitet, der bibeholder det naterulige allergens immunogenitet
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
CA2492823A1 (en) 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
BR0213950A (pt) * 2001-11-07 2004-08-24 Cytos Biotechnology Ag Arranjos de antìgenos para o tratamento de doenças eosinofólicas alérgicas
WO2003039225A2 (en) * 2001-11-07 2003-05-15 Cytos Biotechnology Ag Antigen arrays comprising rankl for treatment of bone disease
EP1532167B1 (en) * 2002-07-17 2012-01-25 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
US20040076645A1 (en) 2002-07-19 2004-04-22 Bachmann Martin F. Ghrelin-carrier conjugates
EP1530585A2 (en) * 2002-08-22 2005-05-18 Cytos Biotechnology AG Inducible alphaviral/orip based gene expression system
AU2003275941A1 (en) 2002-11-01 2004-05-25 Alk-Abello A/S Recombinant protein variants
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
RU2351362C2 (ru) * 2003-03-26 2009-04-10 Цитос Байотекнолоджи Аг КОНЪЮГАТЫ ПЕПТИДА Melan-A, АНАЛОГА ВИРУСОПОДОБНОЙ ЧАСТИЦЫ
WO2004094639A2 (en) 2003-04-24 2004-11-04 Im Vision Gmbh Recombinant fel d 1 allergen
DE602004031017D1 (de) * 2003-07-10 2011-02-24 Cytos Biotechnology Ag Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
US7767212B2 (en) * 2005-03-18 2010-08-03 Cytos Biotechnology Ag CAT allergen conjugates and uses thereof

Also Published As

Publication number Publication date
JP2008535800A (ja) 2008-09-04
MX2007011160A (es) 2007-11-13
CN101141979A (zh) 2008-03-12
ZA200707413B (en) 2009-01-28
WO2006097530A3 (en) 2007-06-21
JP5302671B2 (ja) 2013-10-02
CN101141979B (zh) 2013-05-08
DK1868642T3 (da) 2013-06-24
US20130344098A1 (en) 2013-12-26
RU2007138265A (ru) 2009-04-27
WO2006097530A2 (en) 2006-09-21
IL185103A0 (en) 2007-12-03
EP1868642A2 (en) 2007-12-26
NZ561040A (en) 2009-04-30
CA2599218A1 (en) 2006-09-21
CN103203016A (zh) 2013-07-17
US20110045013A1 (en) 2011-02-24
CA2599218C (en) 2015-08-11
US7767212B2 (en) 2010-08-03
KR20070112225A (ko) 2007-11-22
PL1868642T3 (pl) 2013-10-31
AU2006224529B2 (en) 2012-05-24
US20090175896A1 (en) 2009-07-09
RU2414239C2 (ru) 2011-03-20
EP1868642B1 (en) 2013-05-08
PT1868642E (pt) 2013-07-10
ES2424229T3 (es) 2013-09-30
JP2013155176A (ja) 2013-08-15
BRPI0608455A2 (pt) 2010-01-05
AU2006224529A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
CY1114171T1 (el) Συζευγματα αλλεργιογονων γατας και χρησεις τους
CY1120096T1 (el) Αναγνωριση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια
DE60329106D1 (de) Ghrelin-träger-konjugate
CY1118801T1 (el) Πεπτιδια, προϊοντα συζευξης και μεθοδος για την αυξηση της ανοσογονικοτητας ενος εμβολιου
CY1113546T1 (el) Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
ATE421332T1 (de) Molekulare anordnung von amyloid beta antigenen
EA201991763A1 (ru) Конъюгаты антитела к ccr7 и лекарственного средства
ATE506964T1 (de) Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
NO20054608L (no) Influensavirusvaksine
CY1115935T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
WO2006063974A3 (en) Il-15 antigen arrays and uses thereof
DE60335186D1 (de) Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
BRPI0516953A (pt) partìculas do tipo vìrus compreendendo uma proteìna de fusão da proteìna de revestimento de ap205 e um polipeptìdeo antigênico
DK1443960T3 (da) Antigen-arrays der betegner IL-5, IL-13 eller eotaxin til behandling af allergiske eosinofile sygdomme
EA201291243A1 (ru) Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
CY1109036T1 (el) Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης
DK1441764T3 (da) Antigen-Arrays der omfatter RANKL til behandling af knoglesygdom
MX2010006610A (es) Conjugados de factor de crecimiento de nervios y usos de los mismos.
CY1115168T1 (el) Πεπτιδια fviii και η χρηση τους στην επαγωγη ανοχης των αιμορροφιλικων
CY1110744T1 (el) Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c
DE602005026688D1 (de) Toleranzstudienverfahren bei mhc-ii-transgenen tieren
WO2003059386A3 (en) Prion protein carrier-conjugates
JPWO2009057763A1 (ja) 新規アジュバント
MXPA04003901A (es) Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas.